Select Page

A multinational pharmaceutical company sought support to engage with haemophilia A individuals and caregivers to gather firsthand perspectives on the impact of current and value of future therapies.

Individuals with haemophilia, caregivers, research clinicians and advocates were engaged to support the development of a robust study design, identify volunteers who represented the Canadian haemophilia A population, and offer expert opinion and guidance. Shift Health conducted interviews with 20 volunteers to better understand the challenges with current treatment, impact on quality of life and desired improvements in future therapies. Major themes were validated and prioritized during focus group sessions and a workshop with the study supporters.

Shift Health’s robust approach to information gathering prioritized challenges and desired treatment improvements that informed the development of a peer-reviewed article published in Haemophilia, the official journal of the World Federation of Haemophilia.